VTE prophylaxis for breast surgery; A prospective audit  by Thake, Miriam et al.
Abstracts / International Journal of Surgery 11 (2013) 589e685606
ABSTRACTSIntroduction: Patent Blue V dye is routinely used in the UK for Sentinel
Lymph node biopsy. However, it causes allergic reactions in (0.6-2.7%). The
NEWSTART and ALMANAC studies have reported 1% incidence. The ABS
guidelines 2009, recommends routine consenting for blue dye adminis-
tration and allergic reactions.
Materials and Methods: We looked into 41 cases of WLE/Mastectomy
with SLNB done over a 3 month period. All patients had 2ml of 2.5% PBV
injected subareolarly.
Results: 50% were consented for administration, and only 50% had allergic
responses mentioned. One patient had allergic reaction to blue dye man-
ifesting as intaoperative hypotension requiring ephedrine. There were no
delayed effects. Urticarial rashes, blue hives were seen in 3 patients but
were self-limiting. A similar audit done at a regional tertiary centre, the
consenting rates where 65% despite using pre-printed consent forms
because pre-printed consent forms were not used in all patients.
Conclusion: Patent Blue dye injection is not without risks and therefore
PBV administration and allergic responses to patent blue dye should
routinely be mentioned in consent forms. Using pre-printed forms can
improve the consenting rates, but it requires more awareness and persu-
ation among doctors.0563: THE USE OF CHEST X-RAYS AS A ROUTINE STAGING INVESTIGA-
TION FOR PATIENTS WITH INVASIVE BREAST CANCER e AN AUDIT OF
CURRENT PRACTICE
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2Highland Breast Centre, NHS Highland, Highland, UK.
Aim: We investigated whether patients diagnosed with invasive breast
cancer in NHS Highland received a CXR in line with local preoperative
assessment guidelines.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed if patients received a
pre-operative CXR.
Performing CXRs in 95% was deemed an acceptable audit standard.
Abnormal CXRs were identiﬁed and investigated in more detail.
Results: 111 Patients were diagnosed with invasive breast cancer.
Of the 98 patients who had surgery, 87 had a CXR (89%). Audit standard
failed.
68 CXRs were normal, although metastastic disease was subsequently
identiﬁed in 1 patient. 19 CXRs were abnormal, with 7 CXRs thought to be
due to a metastatic cause.
0 metastases were found in these patients on other imaging modalities.
Conclusions: Routine preoperative CXRs were not being performed in
accordance with local guidelines. Published national guidelines suggest
CXRs are not indicated in asymptomatic patients with invasive breast
cancer and clearly are not an effective tool in our population. Completing
the audit loop was thought unhelpful as this local data has changed
practice and helped suggest a more effective staging strategy.0565: CT OR NOT CT? HOW SHOULD WE LOOK FOR DISTANT METASTA-
SES IN INVASIVE BREAST CANCER IN NHS HIGHLAND?
Hollie Sapsford 1, Nick Abbott 2. 1Raigmore Hospital, NHS Highland, Highland,
UK; 2 The Highland Breast Centre, NHS Highland, Highland, UK.
Aim: Invasive breast cancer can metastasize to distant organs. SIGN(1)
Guidelines (84) suggest that no staging is required for T1-2 N0-1 tumours
in asymptomatic women. We aimed to identify an effective strategy for
staging investigations in NHS Highland.
Method: Data from all patients with invasive breast cancer diagnosed over
a 6 month period were retrieved from a prospectively maintained data-
base. Hospital notes and computer records identiﬁed staging in-
vestigations performed and the presence of conﬁrmed metastases.
Results: 111 patients were diagnosed with invasive breast cancer. 98 had
surgery. 5 were identiﬁed with asymptomatic metastases in the pre/peri-
operative period. 87 CXR were performed. 19 were abnormal. 0 metastases
identiﬁed 28 nucleotide bone scans. 9 abnormal. 2 metastases. 22 Liver USS.
4 abnormal. 0 metastases. 20 CT scans.13 abnormal. 3 metastases.
Conclusions: A low proportion of patients with metastases were identi-
ﬁed. CT chest/abdomen/pelvis is now used as the primary staging inves-
tigation for asymptomatic metastases in patients with preoperative
clinically bulky nodes, 4 nodes positive on post-operative histology and inpatients considered for reconstruction. Correlation with other screening
modalities is used if results are equivocal.
References
(1) SIGN 84 Management of Breast Cancer in Women: A National Clinical
Guideline. December 20050576: MALE BREAST CANCER AND THE ROLE OF GENETIC TESTING:
SHOULD WE INTRODUCE SIMBA (SCREENING IN MALE BREAST
CANCER)?
Simba. Mersey Research Group for Surgery (MeRGS), Mersey, UK.
Aims: To evaluate incidence of male breast cancer in Merseyside, assess
the proportion of BRCA2 carriers and explore if there is a beneﬁt of known
male gene carriers being offered screening.
Method:Retrospective cohort studyof5 centres inMerseyside reviewingmale
patients with breast cancer identiﬁed between 01/01/2000 and 31/10/2012.
Data collected on family history, BRCA gene testing, histology and treatment.
Results: Forty-ﬁve patients identiﬁed; median age 70years (range 37-93).
All presented with a breast lump. Fourty-one(91%) underwent mastec-
tomy; 36(80%) had grade 2/3 disease; 100% were ER+. Fifteen(33%) had
involved lymph-nodes and 10(22%) had lymphovascular invasion. All pa-
tients had anti-endocrine therapy, 6(13%) also underwent chemotherapy.
Six(13%) had family history of breast cancer, 5(11%) had BRCA testing, with
only one(2%) having a BRCA2mutation. The 5 year survial ratewas 62%(16/
26). 36%(4/11) of recorded deaths were related to breast cancer.
Conclusions: Incidence of male breast cancer in Merseyside appears lower
than national average. Findings suggest men have higher grade, ER+ tu-
mours and are likely to undergo mastectomy. Only a small proportion
underwent BRCA testing, raising the question should we be testing all male
breast cancers? Further work is ongoing evaluating BRCA2 rate in Mer-
seyside, in conjunction with Clinical Genetics.0596: ASIT-MAMMARY FOLD PRIZE WINNER: CYTOKERATIN-19 (CK19)
NEGATIVE BREAST CANCERS AND ONE-STEP NUCLEIC ACID AMPLIFICA-
TION (OSNA): MUCH ADO ABOUT NOTHING?
Dionysios-Dennis Remoundos 1, Meera Joshi 1, Farid Ahmed1, Yoon Chia 2,
Giles Cunnick 1,2. 1Department of Breast Surgery, Wycombe Hospital, High
Wycombe, UK; 2Department of Pathology, Wycombe Hospital, High Wycombe, UK.
Background: Sentinel Node Biopsy is standard practice for staging the axilla,
with OSNA more widely used in clinical practice. Nearly all breast cancers
express CK19, andOSNAdetects nodalmetastasis by quantifying the levels of
CK19 mRNA. Limited data exists on the true incidence of CK19-negative tu-
mours. Hence, we investigated the expression of CK19 in our practice.
Methods: All new breast cancer patients in a single centre between May
2010 and May 2012 were identiﬁed retrospectively. The tumour details,
including CK19 status, were retrieved from the pathology reports.
Results: 730 breast cancer patients were identiﬁed. 104 were excluded due
to incomplete data or lack of CK19 immunohistochemical (IHC) staining.
Details from 626 patients were analysed. 16 tumours were CK19-negative
(2.6%). The CK19 status was independent of the tumour histological and
hormone proﬁles. The median age of CK19-negative patients was older
than CK19-positive patients (76 vs 62 respectively).
Conclusions: This is one of the largest series looking at CK19-negative
tumours. As they are rare, routine testing prior to OSNA may not be
necessary. However, the exact correlation between CK19 expression by IHC
and the OSNA results remains uncertain. Studies investigating the pres-
ence or absence of CK19 mRNA may be more appropriate.0655: VTE PROPHYLAXIS FOR BREAST SURGERY; A PROSPECTIVE AUDIT
Miriam Thake, Sheila Shokuhi, Monika Kaushik. Department of Breast and
Oncoplastic Surgery, Glenﬁeld Hospital, University Hospitals of Leicester,
Leicester, UK.
Introduction: Each year approximately 25,000 people die from veno-
thrombolic events, 25 times the number that die from MRSA infection.
There is no consensus in the timing and dose of prophylactic LMWH in
patients undergoing breast surgery. The incidence of VTE in breast surgery
has been shown to be approximately 0.03%.
Aim: To compare the current practice of thromboprophylaxis for patients
undergoing breast surgery with the University Hospitals of Leicester (UHL)
protocol and NICE guidelines to standardise practice.
Sensitivity (%) Speciﬁcity (%) Precision (%) Accuracy (%)
RF
LR
UK data 89.35 83 84.14 86.18
SEER data 75.3 72.4 73.2 73.8
UK data 73.4 66.83 69.04 70.12
SEER data 73.44 66 68 70
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ABSTRACTSMethods: All patients (n¼101) undergoing breast surgery in November
2012 were prospectively audited. The dose, timing and appropriateness
of LMWH administration were reviewed and compared to the UHL
protocol.
Results: 100/101 patients received LMWH with 95% of patients receiving
2500 units and 94% receiving LMWH pre-operatively. Furthermore 7% of
patients received LMWH despite it not being indicated.
Conclusions: The current practice is not standardised and a proportion
of patients (7%) were over-treated. There are no published RCTs con-
cerning the appropriate timing or dose of LMWH for general surgery and
none concerning the use of VTE prophylaxis for breast surgery specif-
ically. The incidence of VTEs or haematomas/haemorrhage is extremely
low so large scale trials would be required to provide statisticially sig-
niﬁcant evidence.
0700: CLINIC LETTERS; HOW WELL ARE WE COMMUNICATING?
Yoon Jung Lee, Jayne Robinson, Alison Waghorn. Royal Liverpool University
Hospital, Liverpool, Mersey, UK.
Introduction: Clinic letters are important for communication between
healthcare professionals and patients. Department of Health guideline
indicates that all patients should receive their clinic letters, but with the
content adjusted. This audit aimed to assess the compliance to the DoH
guideline and highlight the variations between the letters.
Method: Therewere 18 clinics from six consultants eachweek. Clinic letters
for ten randomly selected patients from each clinic bewteen 09/05/12 and
18/05/12 were obtained, including additional referrals. In total, 141 clinic
letters were analysed for primary and additional recipients, and contents.
Results: 51% of the clinic letters were sent to the patients, 26% of which
were achieved by two consultants who primarily addressed to the patients.
Only one letter stated the patient opting out. 46% were in a mix of freeform
and pro-forma while the rest were in freeform. Collectively, 90% of the
letters included clinical presentation with 82% indicating the working
diagnosis but there was a variation between the consultants and clinics.
Conclusion: Currently, the department is not fully complying with the
DoH guideline and should endeavour to improve this. A uniform pro-forma
with additional freeform is also recommended to ensure all important
clinical information is included.
0738: LIPOMODELLING GUIDELINE AUDIT
Philippa Jefferson, Charlotte Ives, Douglas Ferguson. Royal Devon and Exeter
Hospital, Exeter, UK.
Aim: To audit previous practice against the ABS breast lipomodelling
guidelines.
Methods: A retrospective case note review October 2007 until December
2012
Results: 104 procedures, 72 female, 3 male, age 19 to 72 years. 85.33%
following breast cancer surgery. Guidelines suggest patients be:-
Discussed at multidisciplinary meeting with up to date imaging: 7.81% had
MDT recorded within a year of lipomodelling. Five had imaging within a
year of surgery. Non-smokers: 18.66% were smokers at time of procedure.
At least 12 months from radiotherapy: of 38 patients who had radio-
therapy (50.66%) ﬁve (13.16%) had lipomodelling within a year. Followed
up early, 3 months & 1 year: No clear protocol for follow-up identiﬁed.
Given donor site adrenaline inﬁltration: Adrenaline documented in 72%
cases. Guidelines suggest complication rates of: Fat necrosis between 3-
15%: 4.8% in the study; Infections between 0.6-1.1%: 0.96% in the study; No
recurrent breast cancer in patients undergoing lipomodelling was
identiﬁed.
Conclusion: Lipomodelling appears safe with acceptable complication
rates. The ABS/BAPRAS guidelines on safe practice for lipomodelling were
available after most cases had been performed. Breast cancer cases should
be discussed in MDT prior to lipoﬁlling.
0754: THE ROLE OF AXILLARY CLEARANCE FOLLOWING SENTINEL
LYMPH NODE BIOPSY IN BREAST CONSERVING SURGERY
James Warbrick-Smith, Ajay Sahu. North Bristol NHS Trust, Bristol, UK.
Introduction: Current standards of care for clinically node-negative breast
cancer patients undergoing breast conserving surgery dictate that these
women are offered sentinel lymph node biopsy (SLNB) which, if positive, is
followed by axillary lymph node clearance (ALNC). Recent trial evidencefrom Z-0011 and NSABP-B32 suggests that progression to ALNC for some of
these women may be unnecessary. We audited the results of a single
surgeon over 1 year to establish support for this paradigm shift.
Methods: We retrospectively audited pathology reports for women un-
dergoing breast conserving surgery and SLNB followed by ALNC during
2010 at our Trust.
Results: 100women underwent SLNB during the study period, of which 17
were positive and proceeded to ALNC. There was one case of false negative
SLNB. Of the true positive SLNB patients, ALNC revealed nil further
involved nodes in 7 cases (41%), and only 1 further involved node in 4 cases
(24%). In only three cases was level III disease encountered.
Conclusions: In 41% of our cases SLNB itself was effectively therapeutic for
local disease control, and thus ALNC may have been un-necessary. Further
work is required to identify which women may be able to avoid comple-
tion lymphadenectomy.0797: INTRAOPERATIVE INJECTION OF RADIOISOTOPE IS EFFECTIVE IN
THE DETECTION OF SENTINEL LYMPH NODES IN BREAST CANCER
Jeremy Lynch, Ramesh Chandrabhan-Singh, Richard Sainsbury. St Mary's
Hospital, Isle of Wight, UK.
Introduction: The intraoperative identiﬁcation of the sentinel lymph node
(SLN) in breast cancer surgery has been critical to reducing the morbidity
of this operation. The gold standard involves the combined subareolar
injection of blue dye and radioisotope. This is conventionally given before
induction of anaesthesia whilst the patient is awake, which can be painful
and cause anxiety. We hypothesized the injection can be delivered after
induction of anaesthesia without reducing its reliability for identiﬁcation
of the SLN.
Methods: Patients with breast cancer undergoing SLN biopsy from
September 2011 e September 2012 underwent intradermal subareolar
injection of Tc-99 radioiosotope and blue dye immediately after induction
of general anaesthesia.
Results: 70 patients were included with a median age of 64 years. There
was 1 failed localisation. Themean SLNs retrieved per patient was 1.61, and
the mean time to localisation was 21.6 minutes. The negative predictive
was 91.8% and the speciﬁcity was 96.6%.
Conclusion: Injection of radioisotope and blue dye after induction of
anaesthesia reduces pain and still allows reliable identiﬁcation of the SLN.0857: RANDOM FORESTS: THE NEW GENERATION OF MACHINE
LEARNING ALGORITHMS TO PREDICT SURVIVAL IN BREAST CANCER
Asmaa Al-Allak, Gianﬁlippo Bertelli, Paul Lewis. Swansea University,
Swansea, UK.
Aims: With the advent of computer technologies new ‘machine learning’
algorithms (ML) have been developed that employ a variety of statistical,
probabilistic and optimisation tools to ‘learn’ and predict outcomes. The
aimof our studywas to apply such an algorithm to predict survival in breast
cancer and compare its performance to traditional statistical methods.
Methods: The Surveillance Epidemiology and End Results (SEER) and a UK
data base from SouthWales were used to generate predictivemodels based
on a number of predictive factors. Random Forests (RF) was selected as the
ML method and logistic regression (LR) as the traditional method. Model
performance was estimated using sensitivity, speciﬁcity, precision and
accuracy.
Results: the table below summarises the resultsConclusions:We have shown that newML algorithms can outperform the
traditional statistical methods that have in the past been used to generate
tools that predict survival. These new methods can offer a viable alterna-
tive to generate more accurate predictive models with the potential of
improving patient outcomes.
